What is the long-term trend for Harmony Biosciences Holdings, Inc.'s other commercial liabilities?

Over 3 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s other commercial liabilities has grown at a 15.9% compound annual growth rate (CAGR), from $122.73M to $191.04M.

Harmony Biosciences Holdings, Inc. HRMY Other Commercial Liabilities

Other Commercial Liabilities at other companies

Jazz PharmaceuticalsJAZZ

——

XER

Xeris Biopharma Holdings, Inc.XERS

——

Acadia PharmaceuticalsACAD

——

Catalyst PharmaceuticalCPRX

——

Praxis Precision Medicines, Inc.PRAX

——

BiohavenBHVN

——

Other financials

Income statement

See full

Revenue$215.4M+16.6%

Gross profit$170.9M+11.9%

Operating income$37.3M-33.7%

Net income$32.5M-28.7%

EPS (diluted)$0.55-29.5%

Balance sheet

See full

Cash & equivalents$589.4M+20.5%

Total debt$164.6M-7.2%

Total equity$910.3M+26.3%

Total assets$1.3B+20.5%

Cash flow

See full

Operating cash flow$27.8M-18.3%

CapEx$107.0K-79.1%

Free cash flow$126.0M+67.9%

Valuation

See full

Market cap$1.99B-14.9%

Profitability

See full

Gross margin76.5%-1.8pp

Operating margin21.1%-5.1pp

Net margin16.2%-4.3pp

FCF margin40.1%+9.5pp

Returns & leverage

See full

Return on equity17.9%-6.9pp

Debt / equity0.2×-0.1×

Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s other commercial liabilities?: Harmony Biosciences Holdings, Inc. (HRMY) reported other commercial liabilities of $150.11M in Q1 2026.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s other commercial liabilities?: Over 3 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s other commercial liabilities has grown at a 15.9% compound annual growth rate (CAGR), from $122.73M to $191.04M.